Avishay Sella

7.7k total citations · 1 hit paper
105 papers, 3.6k citations indexed

About

Avishay Sella is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Avishay Sella has authored 105 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Pulmonary and Respiratory Medicine, 46 papers in Oncology and 29 papers in Surgery. Recurrent topics in Avishay Sella's work include Renal cell carcinoma treatment (37 papers), Prostate Cancer Treatment and Research (23 papers) and Bladder and Urothelial Cancer Treatments (18 papers). Avishay Sella is often cited by papers focused on Renal cell carcinoma treatment (37 papers), Prostate Cancer Treatment and Research (23 papers) and Bladder and Urothelial Cancer Treatments (18 papers). Avishay Sella collaborates with scholars based in United States, Israel and Spain. Avishay Sella's co-authors include Jae Y. Ro, Christopher J. Logothetis, R. J. Amato, Robert G. Kilbourn, Alberto G. Ayala, C. Logothetis, F. H. Dexeus, Francisco H. Dexeus, Robert J. Amato and David A. Swanson and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Avishay Sella

103 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

1990 463 citations C. Logothetis, F. H. Dexeus et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Avishay Sella

Since Specialization

Citations

This map shows the geographic impact of Avishay Sella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Avishay Sella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Avishay Sella more than expected).

Fields of papers citing papers by Avishay Sella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Avishay Sella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Avishay Sella. The network helps show where Avishay Sella may publish in the future.

Co-authorship network of co-authors of Avishay Sella

This figure shows the co-authorship network connecting the top 25 collaborators of Avishay Sella. A scholar is included among the top collaborators of Avishay Sella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Avishay Sella. Avishay Sella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Breast-Specific Epigenetic Regulation of DeltaNp73 and Its Role in DNA-Damage-Response of BRCA1-Mutated Human Mammary Epithelial Cells 2020 ·Cancers ·Ayelet Avraham, (unknown), Soonweng Cho, (unknown), (unknown), (unknown), Avishay Sella, (unknown), Tanir M. Allweis, Saraswati Sukumar, Ella Evron	3
2	Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial 2019 ·Clinical Genitourinary Cancer ·Sergio Bracarda, Aristotelis Bamias, Jochen Casper, Sylvie Négrier, Avishay Sella, Michael Staehler, Jamal Tarazi, Alessandra Felici, Brad Rosbrook, (unknown), Bernard Escudier	11
3	Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib 2016 ·Annals of Oncology ·Victoria Neiman, Daniel Keizman, David Sarid, J.-L. Lee, Avishay Sella, Maya Gottfried, (unknown), Mario A. Eisenberger, Michael A. Carducci, Victoria J. Sinibaldi, Eli Rosenbaum, (unknown), Avivit Neumann, Wilmosh Mermershtain, Keren Rouvinov, Raanan Berger, İbrahim Yıldız	0
4	Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib? 2015 ·Cancer Research and Treatment ·Daniel Keizman, Keren Rouvinov, Avishay Sella, Maya Gottfried, (unknown), Jaeyeon Kim, Mario A. Eisenberger, Victoria J. Sinibaldi, Avivit Peer, Michael A. Carducci, Wilmosh Mermershtain, Raya Leibowitz‐Amit, Rony Weitzen, Raanan Berger	8
5	Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors. 2014 ·PubMed ·(unknown), Maya Gottfried, (unknown), Avivit Peer, Avivit Neumann, (unknown), Svetlana Kovel, Avishay Sella, Wilmosh Mermershtain, Keren Rouvinov, Ben Boursi, Rony Weitzen, Raanan Berger, Daniel Keizman	9
6	Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma 2012 ·European Journal of Cancer ·Daniel Keizman, Maya Ish‐Shalom, Роберто Пили, Hans J. Hammers, Mario A. Eisenberger, Victoria J. Sinibaldi, Ben Boursi, (unknown), Maya Gottfried, (unknown), Avivit Peer, Svetlana Kovel, Avishay Sella, Raanan Berger, Michael A. Carducci	42
7	A similar cell-specific pattern of HOXA methylation in normal and in cancer tissues 2010 ·Epigenetics ·Ayelet Avraham, Judith Sandbank, Nirit Yarom, Avshalom Shalom, Tami Karni, Itzhak Pappo, Avishay Sella, Alexander Fich, Shlomo Walfisch, Larisa Gheber, Ella Evron	13
8	Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer 2009 ·Annals of Oncology ·Cora N. Sternberg, Herlinde Dumez, Hendrik Van Poppel, Iwona Skoneczna, Avishay Sella, Gedske Daugaard, Thierry Gil, John D. Graham, P. Carpentier, Fabio Calabrò, Laurence Collette, Denis Lacombe	94
9	Combination Chemotherapy following Adrenal Suppression in Androgen– Independent Prostate Cancer 2000 ·European Urology ·Avishay Sella, Dov Flex, Miriam Konichezky, Aarón Sulkes, Jack Baniel	3
10	Phase II trial of 5-fluorouracil, interferon-? and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma 1997 ·Cancer ·Julie A. Ellerhorst, Avishay Sella, Robert J. Amato, Shi‐Ming Tu, Randall E. Millikan, Laury Finn, (unknown), Christopher J. Logothetis	37
11	Phase II trial of 5‐fluorouracil, interferon‐α and continuous infusion interleukin‐2 for patients with metastatic renal cell carcinoma 1997 ·Cancer ·Julie A. Ellerhorst, Avishay Sella, Robert J. Amato, Shi‐Ming Tu, Randall E. Millikan, Laury Finn, (unknown), Christopher J. Logothetis	2
12	Tubular Seminoma:An Immunohistochemical and DNA Flow-cytometric Study of Four Cases 1994 ·American Journal of Clinical Pathology ·Ángel Zavala-Pompa, Jae Y. Ro, Adel K. El‐Naggar, Mahul B. Amin, Nelson G. Ordóǹez, Avishay Sella, Alberto G. Ayala	20
13	Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. 1994 ·Journal of Clinical Oncology ·Avishay Sella, Robert G. Kilbourn, R. J. Amato, (unknown), A. Zukiwski, Julie A. Ellerhorst, C. Logothetis	96
14	Primary carcinoid of the kidney immunohistochemical and ultrastructural studies of five patients 1993 ·Cancer ·(unknown), Jae Y. Ro, Nelson G. Ordóǹez, Mohammed A. Amin, Patricia Troncoso, Alberto G. Ayala, Avishay Sella	50
15	Fine‐needle aspiration cytology of sarcomatoid renal cell carcinoma: A morphologic and immunocytochemical study of 15 cases 1993 ·Diagnostic Cytopathology ·Manon Auger, Ruth L. Katz, Avishay Sella, Nelson G. Ordóñez, David Lawrence, Jae Y. Ro	29
16	Simultaneous renal and transitionalcell carcinomas in same kidney with subsequent lymph node metastasis: DNA flow cytometric study 1991 ·Urology ·(unknown), Jae Y. Ro, Avishay Sella, Alberto G. Ayala	5
17	Circadian Infusion of Floxuridine in Patients with Metastatic Renal Cell Carcinoma 1991 ·The Journal of Urology ·Francisco H. Dexeus, Christopher J. Logothetis, Avishay Sella, Robert J. Amato, Robert G. Kilbourn, Sheryl Ogden, (unknown), (unknown), Robert A. Newman	26
18	Escalated Therapy for Refractory Urothelial Tumors: Methotrexate- Vinblastine-Doxorubicin- Cisplatin Plus Unglycosylated Recombinant Human Granulocyte-macrophage Colony-Stimulating Factor 1990 ·JNCI Journal of the National Cancer Institute ·Christopher J. Logothetis, F. H. Dexeus, Avishay Sella, R. J. Amato, Robert G. Kilbourn, Laury Finn, J. U. Gutterman	86
19	Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. 1990 ·Journal of Clinical Oncology ·F. H. Dexeus, C. Logothetis, Avishay Sella, (unknown), Rosario Amato, James M. Reuben, (unknown)	88
20	Radiation therapy associated invasive bladder tumors 1989 ·Urology ·Avishay Sella, Francisco H. Dexeus, Clayton Chong, Jae Y. Ro, Christopher J. Logothetis	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact